As of Apr 24
| -0.42 / -2.47%|
The 5 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 44.00, with a high estimate of 55.00 and a low estimate of 30.00. The median estimate represents a +165.38% increase from the last price of 16.58.
The current consensus among 6 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.